The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 1 of the 27 sources its claims cite were checked for support.
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design
Open accessAbstract
BACKGROUND: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment. METHODS: After open-label dose optimization (4-week) with LDX, 30-70 mg/d, subjects entered a 2-week randomized, double-blind, placebo-controlled crossover phase. Efficacy assessments included the Permanent Product Measure of Performance (PERMP) total score (attempted+correct) measured predose and from 2 to 14 hours postdose, averaged across postdose sessions (primary) and at each time point vs placebo (secondary), and ADHD Rating Scale IV (ADHD-RS-IV) with adult prompts at baseline and crossover visits. Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, and electrocardiograms. RESULTS: Of 127 randomized subjects, 105 were in the intention-to-treat population and 103 completed the study. While receiving LDX vs placebo, adults had greater improvement (P < .0001) in average PERMP total scores as measured by difference in least squares (LS) mean (95% CI): 23.4 (15.6, 31.2). Absolute (P or=10%) during dose optimization were decreased appetite, dry mouth, headache, and insomnia; no TEAEs >or=5% were reported during crossover phase for adults receiving LDX. CONCLUSIONS: LDX significantly improved PERMP scores vs placebo and maintained improvement throughout the day from the first (2 hours) to last (14 hours) postdose time point vs placebo in adults with ADHD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00697515. Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) http://www.clinicaltrials.gov/ct2/show/NCT00697515?term=NCT00697515&rank=1.
Overview
CoChat Summary
TL;DR
In adults with ADHD, lisdexamfetamine dimesylate (LDX) significantly improved simulated workplace performance and ADHD symptoms versus placebo across the day. Efficacy was demonstrated from 2 to 14 hours postdose, with a safety profile consistent with long-acting stimulants.
Key findings
- On the primary endpoint, average postdose PERMP total score was significantly greater with LDX vs placebo: difference in LS mean (95% CI) 23.4 (15.6, 31.2), P < .0001.
- LDX improved PERMP total scores at every postdose time point from 2 to 14 hours versus placebo (absolute values P ≤ .0017; change from predose P < .001 for each time point).
- ADHD-RS-IV total scores improved significantly with LDX vs placebo: difference in LS mean (95% CI) −11.5 (−14.2, −8.9), P < .0001; CGI-I also favored LDX (P < .0001 by Prescott’s test).
- During dose optimization, common TEAEs (≥10%) were decreased appetite (36.6%), dry mouth (30.3%), headache (19.7%), and insomnia (18.3%); during crossover, no TEAEs were reported by ≥5% of subjects receiving LDX.
Methods
- Randomized, double-blind, placebo-controlled, 2-way crossover study with an open-label dose-optimization phase, conducted at 5 US centers in adults aged 18–55 years with ADHD.
- After 4-week open-label LDX dose optimization (30–70 mg/d), 127 subjects were randomized; 105 were in the intention-to-treat population and 103 completed the study.
- Efficacy was assessed in a simulated adult workplace environment using PERMP at predose and 2, 4, 8, 10, 12, and 14 hours postdose, plus ADHD-RS-IV with adult prompts and CGI; primary analysis used a linear mixed-effects ANOVA with treatment, period, and sequence as fixed effects and subject as random effect.
Limitations
- The paper states the study duration was relatively short; the PERMP setting may increase testing-related arousal, though the simulated AWE includes practice and repeated testing to dampen this; the AWE is only analogous to real-world employment in requiring attention, mental effort, and quantifiable written work.
- The paper states exclusions of subjects with active cardiovascular conditions, other unstable medical conditions, or comorbid psychiatric disorders may limit applicability to clinically encountered populations; the expected 15% dropout rate was exceeded because a hurricane closed one study site.
- Evident from the text: all randomized subjects first underwent open-label dose optimization, so the double-blind comparison was conducted in subjects who tolerated and responded adequately to LDX, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
1 Valid · 0 Not valid · 15 Not checked · 79 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDX demonstrated efficacy vs placebo (P < .0001) by the difference in LS mean (95% CI) for ADHD-RS-IV total scores: -11.5 (-14.2, -8.9).”
§ Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design > Abstract > Results
boostedstates a causen = 127 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvement in average postdose scores was also significantly greater (P < .0001) for adults receiving LDX vs placebo for PERMP-A and PERMP-C scores as measured by the difference in LS mean (Table 3).”
§ Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design > Results > Efficacy
plainstates a causen = 105 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Figure 3 LS mean (SE) change from predose in PERMP-A and PERMP-C scores from 2 to 14 hours postdose (n = 104/104). (LDX = lisdexamfetamine dimesylate; LS = least squares; PERMP-A/-C = Permanent Product Measure of Performance-Attempted/-Correct). PERMP-A: LDX-purple diamonds; Placebo-green diamonds; PERMP-C: LDX-blue circles; Placebo-orange circles.* P < .001 LDX vs placebo.”
§ Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design > Results > Efficacy
plainstates a causen = 104 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Absolute (P ≤ .0017 for each time point) and change from predose (P < .001 for each time point) PERMP total scores were greater at all postdose time points from 2 to 14 h for adults while receiving LDX vs placebo.”
- Also stated in: § Efficacy · boosted
“Analysis of absolute values of total PERMP scores at postdose time points demonstrated significant efficacy for adults while receiving LDX vs placebo at each time point (P ≤ .0017).”
§ Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design > Abstract > Results
boostedstates a causen = 105 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
- Also stated in: § Efficacy · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“TEAEs (≥ 10%) during dose optimization were decreased appetite, dry mouth, headache, and insomnia; no TEAEs ≥ 5% were reported during crossover phase for adults receiving LDX.”
§ Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
48 more claims
Create a free account to see all 95 claims and every source verdict.
- Probably not a substantial claim. 29
- The quote only partly states this claim. 3
- It may state two separate claims as one. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The profile of d-amphetamine delivery by LDX underlies the long daily duration of action of LDX in relieving the hyperactive, inattentive, and impulsive symptoms experienced by patients with ADHD.3,4”
From Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells (2014) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At week 10, LDX compared with placebo was associated with significantly greater improvements in ADHD-RS-IV total scores (P < .0001), with greater reductions from baseline in mean BRIEF-A GEC T scores (P < .0001), and with significantly greater improvements in all the measure’s 9 clinical subscales from baseline (P ≤ .0056).”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, more patients treated with LDX rated as improved on the CGI-I (P ≤ .0125) beginning at week 1 through week 9, and at week 10, 79% of LDX-treated participants were rated as improved, compared with 34.7% of patients receiving placebo (P < .0001).”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Improvements observed from LDX versus placebo in this trial were comparable to those observed in LDX interventions for adults with ADHD [16,27–29].”
From Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine (2024) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in placebo-controlled LDX trials in ADHD, participants were considered treatment “responders” if they had a ≥ 30% reduction in ADHD symptoms using a standardized scale [27–29].”
From Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine (2024) · cites this paper as [28]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Body mass index (lb/in2) | 28.2 (5.45) | 26.6 (4.79) | 27.4 (5.10) | 27.2 (5.02) |”
§ Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design > Results > Demographics and disposition
Reported 174.7 · recomputed 122095.848
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 1×
“Adults with ADHD experience significant impairment [1,3] in multiple domains of daily living, including the workplace, home, and various social settings [3,4].”
Background(1998) · Cited by 2,026
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder
Fayyad, J., De Graaf, R., Kessler, R., Alonso, J., Angermeyer, M., Demyttenaere, K., De Girolamo, G., Haro, J. M., Karam, E. G., Lara, C., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.034389 · Cited by 1,321 · cited 1×
“Attention-deficit/hyperactivity disorder (ADHD) in adults has an estimated prevalence of 4.4% in the United States and 3.4% worldwide [1, 2 ].”
BackgroundInfluentialKaufman Brief Intelligence Test
(2012) · SpringerReference · doi:10.1007/springerreference_183806 · Cited by 1,077
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Biederman, J., Faraone, S. V., Spencer, T. J., Mick, E., Monuteaux, M. C., & Aleardi, M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0403 · Cited by 565 · cited 1×
“Adults with ADHD experience significant impairment [1,3] in multiple domains of daily living, including the workplace, home, and various social settings [3,4].”
BackgroundBiederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404 · cited 2×
“In these studies, LDX demonstrated a safety profile consistent with long-acting stimulant use [15-17].”
BackgroundSpencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402 · cited 1×
“[6-8] have demonstrated efficacy in managing ADHD symptoms in adults [7,9-12].”
Background
Cited by
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
“A post-hoc analysis of the data also showed that the sex and age of the subjects had no significant influence on the efficacy of lisdexamfetamine (Wigal et al., 2010b).”
BackgroundMethodMcElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322
Self-citationBolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
“Lisdexamfetamine, an inactive prodrug for dexamfetamine with limited abuse potential that is licensed for use in adults in the USA and other countries, and in the UK in adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment showed higher effects sizes in one study (Wigal et a…”
McElroy, S. L., Hudson, J., Ferreira-Cornwell, M. C., Radewonuk, J., Whitaker, T., & Gasior, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.275 · Cited by 254
Self-citation
Metadata
- Authors
- Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group
- Affiliations
- University of California, Irvine (US)
- Corresponding author
- Wigal, Timothy
- Venue
- Behavioral and Brain Functions
- Published
- 2010
- Volume
- 6
- Issue
- 1
- Pages
- 34
- ISSN
- 1744-9081 (ISSN-L)
- PMC
- PMC2908054
- OpenAlex
- W2127512142
- Cited by
- 136
- References
- 34
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 13 · 2014: 19 · 2013: 14 · 2012: 18
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Behavioral and Brain Functions (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, adult ADHD, sustained attention, ADHD-RS-IV, treatment-emergent adverse events, stimulant efficacy
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Adult, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotropic Drugs, Time Factors, Work, Treatment Outcome, Cross-Over Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. https://app.cochat.ai/papers/10.1186/1744-9081-6-34
- The paper
- Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group. (2010). Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behavioral and Brain Functions. https://doi.org/10.1186/1744-9081-6-34
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.